Delta样分子4与肿瘤治疗

Delta样分子4（DLIA）在恶性肿瘤高表达可导致血管发生，对恶性肿瘤的生长发育具有促进作用，其下调却可起到抗血管发生的作用，表现肿瘤组织中形成大量无功能的血管，阻碍肿瘤的生长，这一特点使其用于对血管内皮生长因子（VEGF）抑制剂耐受肿瘤的治疗。近来，DLIA单克隆抗体药物进入了临床研究，对耐受VEGF阻滞剂的肿瘤有较好的疗效，但也导致一些不良反应，如能有效预防DLL4的不良作用，将会对恶性肿瘤有更高的临床应用价值。

Delta-like ligand 4 and tumor treatment

Up-regulation of DLL4 contributes to the angiogenesis in malignant tumors, and thus promote tumor growth. While down-regulation of DLL4 would cause antiangiogenesis and restrain tumor growth through forming a large number of no-function blood vessels. Thus it can be used in anti-VEGF tolerant tumors. Recently, DLL4 monoclonal antibody agents have entered clinic studies, and has achieved good curative effect in anti-VEGF tolerant tumors, but there are also some side effects. DLL4 would bring higher clinic value for cancer therapy if the side effects can be prevented effectively.